The pandemic is expected to have a short-term negative impact on the bone growth stimulators market due to a sharp decline in elective surgeries, ban on organized sports, temporary closure of O&P clinics, hospital access restricted to non-essential care, limited access to clinics, and slow-down in-patient flow and referrals. However, gradual signs of recovery can be seen in key European markets as well as China. It is expected that the market will begin to gradually rise as expected from the late second half of 2021, which could be attributed to addressing pre-COVID elective surgeries, growing number of surgeries resulting from clearing backlogs as well as new cases, fully reopened healthcare services, recreation and physical work resumed on a large scale, and the reopening of organized sports. Additionally, long-term growth drivers such as an increase in the geriatric population and the rising prevalence of diabetes, obesity, and osteoarthritis will continue to play a major role in the growth of the market during the forecast period.
Read More